2020 Q3 Form 10-Q Financial Statement
#000156459020052219 Filed on November 09, 2020
Income Statement
| Concept | 2020 Q3 | 2019 Q3 | 2019 Q2 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $12.06M | $7.520M | $5.950M |
| YoY Change | 60.37% | 129.97% | 150.0% |
| % of Gross Profit | |||
| Research & Development | $30.38M | $16.07M | $14.11M |
| YoY Change | 89.05% | 84.59% | 97.38% |
| % of Gross Profit | |||
| Depreciation & Amortization | $400.0K | $400.0K | $400.0K |
| YoY Change | 0.0% | 300.0% | 300.0% |
| % of Gross Profit | |||
| Operating Expenses | $42.44M | $23.58M | $20.06M |
| YoY Change | 79.93% | 96.94% | 110.59% |
| Operating Profit | -$42.44M | -$23.58M | -$20.06M |
| YoY Change | 79.93% | 96.94% | 110.59% |
| Interest Expense | $766.0K | $1.887M | $971.0K |
| YoY Change | -59.41% | 125.72% | 232.53% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$417.0K | -$35.00K | $14.00K |
| YoY Change | 1091.43% | 288.89% | -109.66% |
| Pretax Income | -$42.09M | -$21.73M | -$19.07M |
| YoY Change | 93.7% | 94.92% | 103.3% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$42.09M | -$21.73M | -$19.07M |
| YoY Change | 93.66% | 94.94% | 103.39% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$859.9K | -$469.5K | -$442.3K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 43.19M | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2020 Q3 | 2019 Q3 | 2019 Q2 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $419.8M | $517.0M | $153.1M |
| YoY Change | -18.8% | 167.18% | 138.85% |
| Cash & Equivalents | $104.3M | $308.8M | $36.46M |
| Short-Term Investments | $315.5M | $208.2M | $116.6M |
| Other Short-Term Assets | $5.000M | $3.100M | $1.300M |
| YoY Change | 61.29% | -13.89% | -56.67% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $424.8M | $520.1M | $154.3M |
| YoY Change | -18.32% | 163.75% | 129.9% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $7.340M | $8.427M | $8.734M |
| YoY Change | -12.9% | 10.53% | 158.71% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $2.800M | $802.0K | $802.0K |
| YoY Change | 249.13% | -15.76% | -78.42% |
| Total Long-Term Assets | $15.70M | $15.07M | $15.44M |
| YoY Change | 4.17% | 75.75% | 117.77% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $424.8M | $520.1M | $154.3M |
| Total Long-Term Assets | $15.70M | $15.07M | $15.44M |
| Total Assets | $440.5M | $535.1M | $169.8M |
| YoY Change | -17.69% | 160.08% | 128.74% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $7.600M | $3.823M | $2.966M |
| YoY Change | 98.8% | -11.77% | 53.84% |
| Accrued Expenses | $11.36M | $8.675M | $6.343M |
| YoY Change | 30.94% | 131.83% | 105.81% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $18.90M | $12.50M | $9.309M |
| YoY Change | 51.22% | 54.77% | 85.81% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $7.800M | $8.223M | $8.326M |
| YoY Change | -5.14% | 375.04% | 467.17% |
| Total Long-Term Liabilities | $7.800M | $8.223M | $8.326M |
| YoY Change | -5.14% | 375.04% | 467.17% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $18.90M | $12.50M | $9.309M |
| Total Long-Term Liabilities | $7.800M | $8.223M | $8.326M |
| Total Liabilities | $26.70M | $20.72M | $17.64M |
| YoY Change | 28.85% | 111.31% | 172.23% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$298.7M | -$164.9M | -$143.1M |
| YoY Change | 81.14% | 84.07% | 82.44% |
| Common Stock | $295.2M | ||
| YoY Change | 9237.96% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $413.8M | $514.4M | $152.2M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $440.5M | $535.1M | $169.8M |
| YoY Change | -17.68% | 160.06% | 128.74% |
Cashflow Statement
| Concept | 2020 Q3 | 2019 Q3 | 2019 Q2 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$42.09M | -$21.73M | -$19.07M |
| YoY Change | 93.66% | 94.94% | 103.39% |
| Depreciation, Depletion And Amortization | $400.0K | $400.0K | $400.0K |
| YoY Change | 0.0% | 300.0% | 300.0% |
| Cash From Operating Activities | -$35.82M | -$16.20M | -$14.42M |
| YoY Change | 121.11% | 94.01% | 77.81% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$10.00K | -$80.00K | -$500.0K |
| YoY Change | -87.5% | -96.93% | -69.33% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$15.29M | -$91.43M | $19.78M |
| YoY Change | -83.28% | -5.46% | -144.2% |
| Cash From Investing Activities | -$15.30M | -$91.51M | $19.28M |
| YoY Change | -83.28% | -7.86% | -141.57% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 1.520M | 380.1M | 140.0K |
| YoY Change | -99.6% | 171.43% | -117.07% |
| NET CHANGE | |||
| Cash From Operating Activities | -35.82M | -16.20M | -14.42M |
| Cash From Investing Activities | -15.30M | -91.51M | 19.28M |
| Cash From Financing Activities | 1.520M | 380.1M | 140.0K |
| Net Change In Cash | -49.60M | 272.4M | 5.000M |
| YoY Change | -118.21% | 741.89% | -109.04% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$35.82M | -$16.20M | -$14.42M |
| Capital Expenditures | -$10.00K | -$80.00K | -$500.0K |
| Free Cash Flow | -$35.81M | -$16.12M | -$13.92M |
| YoY Change | 122.15% | 180.84% | 114.81% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2019Q3 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
| CY2020Q3 | us-gaap |
Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
|
0 | |
| CY2019Q3 | us-gaap |
Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
|
0 | |
| CY2020Q3 | us-gaap |
Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
|
0 | |
| CY2019Q3 | us-gaap |
Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
|
0 | |
| CY2020Q3 | us-gaap |
Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
|
0 | |
| CY2019Q3 | us-gaap |
Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
|
0 | |
| CY2020Q3 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
|
0 | |
| CY2019Q3 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
|
0 | |
| CY2020Q3 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
|
0 | |
| CY2019Q3 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
|
0 | |
| CY2020Q3 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
|
0 | |
| CY2019Q3 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
|
0 | |
| CY2020Q3 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
|
0 | |
| CY2019Q3 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
|
0 | |
| CY2020Q3 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:AccruedLiabilitiesCurrent | |
| CY2020Q3 | us-gaap |
Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherLiabilitiesNoncurrent | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherLiabilitiesNoncurrent | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:AccruedLiabilitiesCurrent | |
| CY2020Q3 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
828000 | |
| CY2020Q3 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
|
698000 | |
| CY2020Q3 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
|
0 | |
| CY2020Q3 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-620000 | |
| CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-42086000 | |
| CY2020Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
413812000 | |
| CY2019Q3 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
1934000 | |
| CY2020Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
7989000 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
|
595000 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
|
6000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
45000 | |
| CY2019Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3105000 | |
| CY2019Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
138000 | |
| CY2019Q2 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
|
6000 | |
| CY2019Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
84000 | |
| CY2019Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-19072000 | |
| CY2019Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
152150000 | |
| CY2019Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3960000 | |
| CY2019Q3 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
|
595000 | |
| CY2019Q3 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
377525000 | |
| CY2019Q3 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
|
6000 | |
| CY2019Q3 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-12000 | |
| CY2019Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-21732000 | |
| us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
0 | ||
| allk |
Vesting Of Restricted Common Stock Subject To Repurchase
VestingOfRestrictedCommonStockSubjectToRepurchase
|
0 | ||
| allk |
Vesting Of Restricted Common Stock Subject To Repurchase
VestingOfRestrictedCommonStockSubjectToRepurchase
|
18000 | ||
| CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-42086000 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-19953000 | |
| allk |
Available For Sale Securities Gross Recognized Gains On Sale Or Maturity
AvailableForSaleSecuritiesGrossRecognizedGainsOnSaleOrMaturity
|
0 | ||
| allk |
Available For Sale Securities Gross Recognized Losses On Sale Or Maturity
AvailableForSaleSecuritiesGrossRecognizedLossesOnSaleOrMaturity
|
0 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1100000 | ||
| CY2020Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
7752000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
8112000 | |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1162000 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1117000 | ||
| CY2019Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
514426000 | |
| us-gaap |
Profit Loss
ProfitLoss
|
-109202000 | ||
| us-gaap |
Profit Loss
ProfitLoss
|
-60757000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
23240000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
9899000 | ||
| us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-1659000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
76000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
696000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
141422000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-62109000 | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
377525000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
2569000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
2440000 | ||
| us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
|
1454000 | ||
| us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
|
1190000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
4023000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
381155000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
65936000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
275145000 | ||
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
40642000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
34462000 | |
| us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
2083000 | ||
| allk |
Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
|
217000 | ||
| allk |
Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
|
207000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
2088000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-292000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
1602000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
1731000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
3901000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
5652000 | ||
| us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
0 | ||
| us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
41000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-79509000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-43901000 | ||
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
270302000 | ||
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
259413000 | ||
| us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
411800000 | ||
| us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
198000000 | ||
| CY2020Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
106578000 | |
| CY2019Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
309607000 | |
| us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
0 | ||
| us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
6050000 | ||
| us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
16000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-109200000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-79500000 | ||
| CY2020Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-298700000 | |
| CY2020Q3 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
419800000 | |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management uses significant judgment when making estimates related to common stock valuation and related stock-based compensation expense, accrued expenses related to clinical trials, calculation of right-of-use assets and lease liabilities, and deferred tax valuation allowances. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates under different assumptions or conditions, and those differences could be material to the financial position and results of operations. </p> | ||
| us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to credit risk principally consist of cash, cash equivalents and marketable securities. These financial instruments are held in accounts at a single financial institution that management believes possesses high credit quality. Amounts on deposit with this financial institution have and will continue to exceed federally-insured limits. The Company has not experienced any losses on its cash deposits. Additionally, the Company’s investment policy limits its investments to certain types of securities issued by or backed by the U.S. government and its agencies. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks similar to that of other clinical stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future clinical trials, its reliance on third-</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its product candidates, competitive developments, the need to successfully commercialize and gain market acceptance of the Company’s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, the ability to make milestone, royalty or other payments due under licensing agreements, and the need to secure and maintain adequate manufacturing arrangements with third-parties. If the Company does not successfully commercialize or partner its product candidates, it will be unable to generate product revenue or achieve profitability.</span></p> | ||
| CY2020Q3 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
2300000 | |
| CY2020Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
104303000 | |
| CY2019Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
38367000 | |
| CY2020Q3 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
2275000 | |
| CY2019Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
2275000 | |
| CY2020Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
106578000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
40642000 | |
| CY2019Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
308805000 | |
| CY2018Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
33660000 | |
| CY2019Q3 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
802000 | |
| CY2018Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
802000 | |
| CY2019Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
309607000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
34462000 | |
| CY2020Q3 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
| CY2020Q3 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
| CY2019Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-21732000 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-109202000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-60757000 | ||
| CY2020Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
48950000 | |
| CY2019Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
46280000 | |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
48819000 | ||
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
44025000 | ||
| CY2020Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.86 | |
| CY2019Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.47 | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.24 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.38 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
7627000 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
7064000 | ||
| CY2019Q3 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
| CY2020Q3 | us-gaap |
Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
|
0 | |
| CY2019Q3 | us-gaap |
Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
|
0 | |
| CY2020Q3 | us-gaap |
Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
|
0 | |
| CY2019Q3 | us-gaap |
Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
|
0 | |
| CY2020Q3 | us-gaap |
Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
|
0 | |
| CY2019Q3 | us-gaap |
Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
|
0 | |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
|
0 | ||
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
|
0 | ||
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
|
0 | ||
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
|
0 | ||
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
|
0 | ||
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
|
0 | ||
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
|
0 | ||
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
|
0 | ||
| CY2020Q3 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
315285000 | |
| CY2020Q3 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
168000 | |
| CY2020Q3 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
1000 | |
| CY2020Q3 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
315452000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
457397000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
161000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
24000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
457534000 | |
| CY2020Q3 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
|
30300000 | |
| CY2019Q4 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
|
187400000 | |
| CY2019Q3 | allk |
Available For Sale Securities Gross Recognized Gains On Sale Or Maturity
AvailableForSaleSecuritiesGrossRecognizedGainsOnSaleOrMaturity
|
0 | |
| CY2019Q3 | allk |
Available For Sale Securities Gross Recognized Losses On Sale Or Maturity
AvailableForSaleSecuritiesGrossRecognizedLossesOnSaleOrMaturity
|
0 | |
| allk |
Available For Sale Securities Gross Recognized Losses On Sale Or Maturity
AvailableForSaleSecuritiesGrossRecognizedLossesOnSaleOrMaturity
|
0 | ||
| CY2020Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
7340000 | |
| allk |
Available For Sale Securities Gross Recognized Gains On Sale Or Maturity
AvailableForSaleSecuritiesGrossRecognizedGainsOnSaleOrMaturity
|
0 | ||
| CY2020Q3 | allk |
Available For Sale Securities Gross Recognized Gains On Sale Or Maturity
AvailableForSaleSecuritiesGrossRecognizedGainsOnSaleOrMaturity
|
0 | |
| CY2020Q3 | allk |
Available For Sale Securities Gross Recognized Losses On Sale Or Maturity
AvailableForSaleSecuritiesGrossRecognizedLossesOnSaleOrMaturity
|
0 | |
| CY2020Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
10538000 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
10446000 | |
| CY2020Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
3198000 | |
| CY2019Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2036000 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
8410000 | |
| CY2020Q3 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
400000 | |
| CY2019Q3 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
400000 | |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1200000 | ||
| CY2020Q3 | allk |
Accrued Contract Research And Development Expense Current
AccruedContractResearchAndDevelopmentExpenseCurrent
|
4528000 | |
| CY2019Q4 | allk |
Accrued Contract Research And Development Expense Current
AccruedContractResearchAndDevelopmentExpenseCurrent
|
4990000 | |
| CY2020Q3 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
5992000 | |
| CY2019Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
1608000 | |
| CY2020Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
471000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
410000 | |
| CY2020Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
368000 | |
| CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
90000 | |
| CY2020Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
11359000 | |
| CY2019Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
7098000 | |
| CY2020Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
471000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
410000 | |
| CY2020Q3 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
8223000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
8522000 | |
| CY2020Q3 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
280000 | |
| CY2019Q3 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
279000 | |
| us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
838000 | ||
| us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
839000 | ||
| CY2020Q3 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
87000 | |
| CY2019Q3 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
83000 | |
| us-gaap |
Variable Lease Cost
VariableLeaseCost
|
261000 | ||
| us-gaap |
Variable Lease Cost
VariableLeaseCost
|
259000 | ||
| CY2020Q3 | us-gaap |
Lease Cost
LeaseCost
|
367000 | |
| CY2019Q3 | us-gaap |
Lease Cost
LeaseCost
|
362000 | |
| us-gaap |
Lease Cost
LeaseCost
|
1099000 | ||
| us-gaap |
Lease Cost
LeaseCost
|
1098000 | ||
| CY2020Q3 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
313000 | |
| CY2020Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
1270000 | |
| CY2020Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
1308000 | |
| CY2020Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
1348000 | |
| CY2020Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
1388000 | |
| CY2020Q3 | allk |
Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
|
6916000 | |
| CY2020Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
12543000 | |
| CY2020Q3 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
4320000 | |
| CY2020Q3 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
8223000 | |
| CY2020Q3 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
300000 | |
| CY2019Q3 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
300000 | |
| us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
800000 | ||
| us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
800000 | ||
| CY2020Q3 | us-gaap |
Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
|
P8Y9M18D | |
| CY2020Q3 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.100 | |
| CY2020Q3 | us-gaap |
Purchase Obligation
PurchaseObligation
|
63600000 | |
| CY2020Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
7989000 | |
| CY2019Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3960000 | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
23240000 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
9899000 | ||
| CY2020Q3 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | |
| us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | ||
| CY2019Q3 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | |
| us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | ||
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
7148000 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
12.96 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
144000 | ||
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
70.89 | ||
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
244000 | ||
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
10.54 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
27000 | ||
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
19.08 | ||
| CY2020Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
7021000 | |
| CY2020Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
14.21 | |
| CY2020Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
4853000 | |
| CY2020Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
7.95 | |
| CY2020Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
7004000 | |
| CY2020Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
14.16 | |
| CY2020Q3 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
34900000 |
